Posts

Real-World Evidence in Orthopedic Implants Why Post-Market Intelligence Is Reshaping Device Strategy

Image
  Executive Overview The orthopedic implant industry is entering a new era of accountability. Regulators, payers, hospital systems, and patients no longer evaluate implants solely on the basis of controlled clinical trial performance. Increasingly, they expect evidence demonstrating how devices perform across diverse patient populations, surgical environments , and extended time horizons in routine clinical practice. Randomized controlled trials (RCTs) remain essential for establishing baseline safety and efficacy. However, they are inherently limited by narrow enrollment criteria, controlled treatment conditions, and relatively short follow-up periods. These constraints leave critical questions unanswered regarding long-term survivorship, real-world complications, utilization patterns, and economic value. Real-world evidence (RWE) has emerged as the strategic bridge between regulatory approval and lifelong performance validation. By integrating data from registries, claims systems...
Post a Comment
Read more

The Architectural Shift in Depression Why Brain Network Topology Is Redefining CNS Strategy

Image
  By Denis Katz, MD, MHA Founder, Salience Clinical Beyond the Chemistry Paradigm For decades, major depressive disorder (MDD) has been framed as a disorder of neurotransmitters primarily serotonin, norepinephrine, and dopamine. This model enabled meaningful therapeutic progress, but its limits are increasingly clear. A large proportion of patients do not achieve sustained remission. Treatment resistance remains common, and relapse rates are high even among responders. These realities suggest that incremental adjustments to synaptic signaling have reached a practical ceiling in their ability to reshape long-term outcomes. The next transformation in neuropsychiatry will not be driven by chemistry alone. It will be driven by architecture. An Architectural Lens on Depression By architecture, we refer to the structure and dynamics of large-scale brain networks—how they connect, interact, and transition over time. Over the past decade, advances in functional imaging, multimodal data ...
Post a Comment
Read more

Navigating Regulatory Complexity in Alzheimer’s Drug Development

Image
  De-Risking Investment, Preserving Capital, and Building Approval-Ready Programs Denis Katz, MD, MHA Clinical Scientist & Development Strategist Founder, Salience Clinical, LLC Executive Overview Alzheimer’s disease (AD) remains one of the most capital-intensive and failure-prone areas in biopharma. Decades of high-profile setbacks created what many termed the Alzheimer’s graveyard. Yet recent approvals targeting amyloid biology have demonstrated a critical shift: regulatory pathways are viable but only when programs are designed with precision and foresight. In 2026, success is defined by translational coherence  the ability to demonstrate that biological intervention leads to measurable and meaningful clinical outcomes. The central challenge is no longer simply proving target engagement, but establishing a credible bridge from molecular change to patient-level benefit. The Persistent Success Gap Near-total historical attrition: Failure rates approached 99% across early...
Post a Comment
Read more

Precision Neurology 2026 From Syndromes to Signatures: Re-Architecting CNS Drug Development

Image
  Executive Perspective For decades, neurology has relied on syndromic definitions groupings of observable symptoms used as proxies for underlying disease. That framework is rapidly losing relevance. Today, central nervous system (CNS) disorders are being redefined through molecular signatures, circuit-level dysfunction, and continuously captured digital phenotypes. This shift is not incremental it fundamentally alters how therapies must be discovered, developed, and approved. Organizations that continue to anchor development programs in broad diagnostic labels and legacy endpoints face a growing risk of failure. Not because their science lacks merit, but because their development strategies are misaligned with biological reality. Salience Clinical operates at the intersection of neuroscience, regulatory strategy, and clinical execution helping sponsors convert biological insight into approvable therapies, differentiated labels, and durable commercial value. Audience: Chief Medica...
Post a Comment
Read more

Navigating Regulatory Hurdles in Alzheimer’s Drug Development

Image
  Protecting Sponsor Capital, Managing Risk, and Maximizing Probability of Success Denis Katz, MD, MHA Clinical Scientist & Development Strategist Founder, Salience Clinical, LLC Executive Summary Alzheimer’s disease (AD) drug development remains the most high-risk, high-investment domain in biopharma. The so-called “Alzheimer’s graveyard” reflects decades of scientific promise undermined by regulatory, operational, and strategic misalignment. However, the landscape is evolving. The emergence of amyloid- and tau-targeting therapies has demonstrated that regulatory success is achievable when supported by disciplined development strategy and risk architecture. In 2026, success is defined by translational clarity : the ability to demonstrate that biological modification leads to meaningful and measurable clinical benefit. The Success Gap 99.6% historical failure rate (2002–2012) 18-year gap between approvals of novel disease-modifying therapies $300M+ average cos...
Post a Comment
Read more

Precision Neurology 2026 From Syndromes to Signatures: The Strategic Rewiring of CNS Drug Development

Image
  Executive Summary For decades, neurology has operated within a syndromic framework grouping patients by observable symptoms rather than underlying biology. That model is reaching its limits. CNS disorders are now being redefined through molecular signatures, circuit-level dysfunction, and digital phenotypes . This is not a technological evolution it is a structural reset of how drugs are developed, evaluated, and approved. Sponsors who continue to build programs around broad diagnostic categories and legacy endpoints will increasingly fail not because their science lacks merit, but because their development strategy is misaligned with biological reality. Salience Clinical operates at the intersection of neuroscience, regulatory strategy, and precision development helping sponsors translate biological complexity into approvable labels, differentiated value , and durable market position . Target Audience: Chief Medical Officers, Heads of R&D, and Clinical Development Leaders a...
Post a Comment
Read more